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A B S T R A C T
A comprehensive review of the neurological disorders reported during the current COVID-19 pandemic de-
monstrates that infection with SARS-CoV-2 affects the central nervous system (CNS), the peripheral nervous
system (PNS) and the muscle. CNS manifestations include: headache and decreased responsiveness considered
initial indicators of potential neurological involvement; anosmia, hyposmia, hypogeusia, and dysgeusia are
frequent early symptoms of coronavirus infection. Respiratory failure, the lethal manifestation of COVID-19,
responsible for 264,679 deaths worldwide, is probably neurogenic in origin and may result from the viral in-
vasion of cranial nerve I, progressing into rhinencephalon and brainstem respiratory centers. Cerebrovascular
disease, in particular large-vessel ischemic strokes, and less frequently cerebral venous thrombosis, intracerebral
hemorrhage and subarachnoid hemorrhage, usually occur as part of a thrombotic state induced by viral at-
tachment to ACE2 receptors in endothelium causing widespread endotheliitis, coagulopathy, arterial and venous
thromboses. Acute hemorrhagic necrotizing encephalopathy is associated to the cytokine storm. A frontal hy-
poperfusion syndrome has been identified. There are isolated reports of seizures, encephalopathy, meningitis,
encephalitis, and myelitis. The neurological diseases affecting the PNS and muscle in COVID-19 are less frequent
and include Guillain-Barré syndrome; Miller Fisher syndrome; polyneuritis cranialis; and rare instances of viral
myopathy with rhabdomyolysis. The main conclusion of this review is the pressing need to define the neurology
of COVID-19, its frequency, manifestations, neuropathology and pathogenesis. On behalf of the World
Federation of Neurology we invite national and regional neurological associations to create local databases to
report cases with neurological manifestations observed during the on-going pandemic. International neuroepi-
demiological collaboration may help define the natural history of this worldwide problem.
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Coronavirus disease 2019 (COVID-19) is a severe acute respiratory
syndrome (SARS) caused by the SARS-CoV-2 coronavirus that since
December 2019 reached pandemic proportions causing in 5months
more than 3 million confirmed cases worldwide and over 260.000
deaths [Johns Hopkins University Coronavirus Resource Center:
https://coronavirus.jhu.edu]. Recent publications [1–3] have described
neurological manifestations in COVID-19 involving the central nervous
system (CNS), peripheral nervous system (PNS) and muscle, as well as
early alterations of olfaction and taste [4]. The Environmental Neu-
rology Specialty Group of the World Federation of Neurology concluded
that the potential neurological involvement in COVID-19 is a topic of
major importance that necessitates a global effort to obtain the neu-
roepidemiological and clinical data required to quantify the magnitude
of the problem, to define the full range of the neurological disease and
to encourage neuropathological, physiopathological and therapeutic
research. We proposed the creation of international COVID-19 neuro-
logical registries to collect and assemble data on acute, chronic and any
long-latency effects on the infection on the nervous system [5]. This
followed the example of the Spanish Neurological Society (Sociedad
Española de Neurología, SEN) [www.sen.es] that, in the midst of one of
the most severe outbreaks of COVID-19 in Europe, managed to imple-
ment a registry of de novo acute and subacute neurological manifes-
tations in patients with confirmed SARS-CoV-2 infection.
We provide in this review updated information on the known neu-
rological consequences of coronavirus infection in severe acute re-
spiratory syndrome (SARS) and Middle East respiratory syndrome
(MERS), as well as selected published data on nervous system injury
observed in animal models. We conclude with a current review of
neurological manifestations reported in patients with COVID-19. Future
research will define issues of congenital involvement –such as seen in
maternal infections with Zika virus– or long-latency brain disorders
following in utero, perinatal or early childhood infections. While pre-
sently unknown in COVID-19, we should be alert to the possibility of
tardive disorders comparable to measles-associated Subacute Sclerosing
Panencephalitis or Progressive Rubella Panencephalitis; as well as long-
term neurological disease, for example late Parkinsonism that occurred
among survivors of Encephalitis Lethargica [6] during the 1918–1920
influenza pandemic [7] and, more recently, the increased risk of nar-
colepsy observed in 2009–2010 after the swine flu pandemic due to
influenza A with concurrent vaccination using a monovalent H1N1
influenza vaccine [8].
2. Coronaviruses
According to Henry [9], the name “coronavirus,” from the Latin
corona (crown), was coined in 1967 by June Almeida [10] based on
ultrastructural images resembling the solar corona that she obtained of
human cold viruses and the avian infectious bronchitis virus [11]. Since
then, a large number of avian, feline, canine, porcine, bovine and
equine coronaviruses of veterinary interest has been described as
etiological agents of respiratory and enteric diseases [12]. A cor-
onavirus characterized as porcine hemagglutinating encephalomyelitis
virus (PHEMV) causes respiratory symptoms and encephalomyelitis in
pigs. It was first isolated in 1962 in Canada [13] but became an en-
demic worldwide zoonosis reported as late as 2015 at animal fairs in
Michigan and Ohio, USA [14].
Coronaviruses were considered minor human pathogens until the
2002–2003 outbreak of SARS in Guangdong, China, that eventually
affected 8096 people and caused at least 774 deaths worldwide (mor-
tality rate 9.6%), according to the World Health Organization (WHO).
SARS-CoV (now called SARS-CoV-1) [15,16] originated in bats (Rhi-
nolophus affinis) and reached humans via badgers (Melogale moschata),
Himalayan palm civets (Paguma larvata), and raccoon dogs (Nyctereutes
procyonoides) [17]. This SARS epidemic outbreak demonstrated the
capacity of coronaviruses to infect humans and to jump across species
[15–17], most likely from bat reservoirs [18–20].
Ten years later, in 2012, another outbreak of a highly pathogenic
coronavirus, MERS-CoV [21,22], caused 2494 confirmed cases and 858
deaths according to WHO data (case-fatality rate: 34.4%) particularly in
Saudi Arabia [23]. MERS may have also originated from bats [20] and
utilized camels and dromedaries as intermediary hosts [24,25]. Evi-
dence of camel-to-human infection occurred initially in the Arabian
Peninsula [26] followed by viral spread that included nosocomial in-
fections [23].
The current COVID-19 pandemic emerged in December 2019 in
Wuhan, China. A zoonotic origin of the etiological agent, SARS-CoV-2,
was confirmed with viral isolation from reservoirs in bats that infected
as intermediate host the Malayan pangolin (Manis javanica) and other
wildlife used for food in China [27,28]. These outbreaks have solidly
confirmed the high infectivity and lethality of the coronaviruses that
pose serious threats to Public Health around the world.
2.1. Taxonomy and structure
The coronaviruses (CoV) are members of the Coronavirinae sub-
family. The Torovirinae plus the coronaviruses comprise the
Coronaviridae family in the order Nidovirales [21]. CoVs are classified in
four different genera: alpha, beta, gamma, and delta-CoV according to
their phylogenetic links and genomic structures. The Coronaviridae
members MERS-CoV, SARS-CoV-1, and SARS-CoV-2 all belong to the
beta-coronavirus (β-CoV) genus and share highly homologous genomic
sequences [21].
The coronaviruses are enveloped single-stranded ribonucleic acid
(RNA) viruses with the largest known RNA genome, ranging from 26.2
to 31.7 kilobases [21]. The genome contains a 5′ cap and is composed of
six to ten open reading frames (ORFs). There are three main viral
proteins in the envelope of the virion: the spike protein (S), the mem-
brane protein (M) and the envelope protein (E). The spike glycoprotein
mediates virus entry and determines the range of potential hosts, cell
tropism and disease pathogenesis [29]. SARS-CoV-1 and SARS-CoV-2
use angiotensin-converting enzyme 2 (ACE2) as receptor to infect ci-
liated bronchial epithelial cells and type II pneumocytes [20], which
explains the severity of the pulmonary involvement. SARS-CoV-2 has a
higher affinity than SARS-CoV-1 for the ACE2 receptor, which is present
in neurons and endothelial cells indicating that SARS-CoV-2 may have
higher neuroinvasive potential compared to previous coronaviruses
[30]. MERS-CoV uses dipeptidyl peptidase 4 (DPP4) receptor and the
carcinoembryonic antigen–related cell-adhesion molecule 5
(CEACAM5) cofactor ligand to infect unciliated bronchial cells [20].
After binding to the receptor, viruses fuse their envelope with the host
cell membrane and the nucleocapsids reach the target cell. The fusion
involves large conformational changes of the spike protein [31].
3. Animal models of neurotropic coronavirus infections
Four decades of research on respiratory coronaviruses have de-
monstrated the capacity of these viruses to go beyond the respiratory
system to enter the nervous system and establish persistent brain in-
fection of animals with or without induction of neurological illness
[30,32]. There is abundant experimental animal evidence that cor-
onaviruses can reach the brain via spillage from the lungs to the cir-
culatory system or by axonal transport and transneuronal spread from
olfactory and trigeminal nerve endings in the nasal epithelium [30,32].
Some coronaviruses experimentally can spread from airway mechan-
oreceptors and chemoreceptors to the medullary cardio-respiratory
centers [33]. Viruses can also access the nervous system via the cir-
cumventricular organs [34] that normally lack a blood-brain barrier
(BBB) and via dorsal root ganglia and autonomic (including cardiac)
ganglia [35] both of which have no blood-nerve barrier (BNB). Indeed,
the previously mentioned swine coronavirus PHEMV can establish
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ganglionic infection of sensory neurons in dorsal root ganglia after
peripheral inoculation [35].
Since SARS-CoV-2 can infect the vascular endothelium of peripheral
organs (kidney lung, heart, kidney, and liver) this raises the question of
BBB/BNB disruption by direct infection of the endothelium of neural
vasculature. Varga and colleagues [36] demonstrated SARS-CoV-2
causes infection of endothelial cells and endotheliitis; thereby, systemic
vascular endotheliitis promotes vasoconstriction, edema and a pro-
coagulate state [37] with important implications relevant to cere-
brovascular stroke. According to Flammer et al. [38] the vascular en-
dothelium is an active paracrine, endocrine, and autocrine organ that is
indispensable for the regulation of vascular tone and the maintenance
of vascular homoeostasis. Endothelial microvascular dysfunction leads
to vasoconstriction with subsequent organ ischemia, inflammation with
associated tissue edema, and a pro-thrombotic state [37,38]. En-
dothelial dysfunction is also an important factor for atherosclerosis
[37,38]
Experimental studies with the mouse hepatitis virus (MHV) illus-
trate the potential neurological effects of infection with a neurotropic
coronavirus [39]. Neurotropic MHV strains induce an acute en-
cephalitis in mice, while animals that survive the acute infection dis-
play chronic brain demyelination, which has been used to model mul-
tiple sclerosis (MS) [40]. Of interest, Yeh et al. [41] used reverse
transcriptase polymerase chain reaction (RT-PCR) to demonstrate
human coronavirus (HCoV OC43) RNA in the cerebrospinal fluid (CSF)
and nasopharyngeal secretions of a 15-year-old boy with acute eleva-
tion of circulating anti-HCoV antibodies and evidence on Magnetic
Resonance Imaging (MRI) of the brain of demyelinating lesions diag-
nosed as Acute Disseminated Encephalomyelitis (ADEM), although MS
could not be ruled out. Moreover, human coronavirus RNA has been
demonstrated in CSF [42] and in brains of patients with MS [43,44].
Arbour and colleagues [45] using RT-PCR demonstrated the presence of
HCoV RNA in 44% of brain tissue samples from 90 patients with neu-
ropathology-proven MS.
4. Neurological involvement in SARS and MERS patients
During the epidemic outbreaks of SARS in China and MERS in Saudi
Arabia, neurological signs and symptoms were reported in small num-
bers of patients infected with the respiratory coronaviruses SARS-CoV-1
and MERS-CoV respectively. Neuropathological data from those pa-
tients are also available in limited cases, as described below.
4.1. SARS in China 2002–2003
In 2007, Gu and Korteweg [46] reported a dozen autopsies of SARS
patients; using RT-PCR on postmortem tissue they demonstrated SARS-
CoV-1 viral RNA and genomic sequences in the cytoplasm of hy-
pothalamic and cerebral cortical neurons of confirmed SARS cases.
Brain edema and focal degeneration of neurons was found together
with ultrastructural confirmation of viral infection of neurons and glial
cells by SARS-CoV-1. Neuropathological changes included degeneration
and necrosis of neurons, extensive glial cell hyperplasia, and cellular
infiltrates, but demyelination was not present. Xu and colleagues [47]
isolated a SARS coronavirus strain from brain tissue of a patient with
SARS and symptoms of severe CNS involvement. Pathologic examina-
tion of the brain revealed necrosis of neurons and gliosis. In addition,
by immunostaining tissue sections they showed that a monokine in-
duced by interferon-Γ (Mig) was expressed in glial cells along with
infiltration of CD68+ monocytes/macrophages and CD3+ T lympho-
cytes in the brain parenchyma. Blood levels of interferon-Γ–inducible
protein 10 and Mig in the blood were highly elevated but other cyto-
kines and chemokines were normal [47].
SARS-CoV meningoencephalitis was demonstrated using RT-PCR in
CSF to detect viral RNA in two patients with severe respiratory symp-
toms and generalized seizures admitted to the hospital during the se-
vere outbreak of SARS in Hong Kong [48]; one was a 59-year-old
woman in status epilepticus [49] and the second patient was a 32-year-
old pregnant woman [50].
Involvement of the PNS was also reported in SARS occurring
2–3 weeks after onset of infection with features of axonal peripheral
neuropathy [51,52]. A myopathy with elevated creatinine kinase was
also reported [53]. Focal myocyte necrosis in skeletal muscle was found
in SARS autopsy cases [46,53,54], probably caused by diffuse vasculitis
[50]. A single case of olfactory neuropathy occurring 3 weeks after
infection with SARS-CoV-1 was reported in Taiwan [55].
In a cohort of 206 SARS patients in Singapore [56] 5 had large-
vessel strokes (2.4% or about 1 in 42 SARS infections); 4 of them were
critically ill and 3 died. There was concern of enhanced thrombosis risk
from using intravenous immunoglobulin (IVIg) given the observed
higher incidence of deep venous thrombosis and pulmonary embolism.
A Canadian study of 22 health-care workers assessed 13–36months
after the 2003 outbreak of SARS found that chronic post-SARS-CoV
infection was characterized by persistent fatigue, diffuse myalgia,
weakness, depression, and non-restorative sleep with associated REM-
related apneas/hypopneas, an elevated sleep EEG cyclical alternating
pattern, and alpha EEG sleep anomaly [57]. These disorders
Table 1
SARS: pathological findings (According to Gu & Korteweg, 2007 [46]).
Organs/Tissue Pathology # Cases
Central nervous system Edema and degeneration of neurons, positive neurons by in situ hybridization 12
Skeletal Muscles Myofiber necrosis and atrophy, few regenerative myofibers 13
Heart Edema and atrophy of myocardial fibers 22
Respiratory tract Diffuse alveolar damage with varying degrees of acute exudative features including edema, hyaline membranes, organization, and fibrosis.
Macrophagic or mixed cellular infiltration, multinuclear giant cells, atypical reactive pneumocytes, and vascular injury. Positive in situ
hybridization in pneumocytes, lymphocytes, and macrophages
63
Spleen and lymph nodes Lymphocyte depletion in spleen and lymph nodes with architectural disruption. Splenic white pulp atrophy. Positive in situ hybridization signals
in immune cells
25
Digestive tract Intestines: No obvious pathology, nonspecific lesions. Depletion of mucosal lymphoid tissue. Positive in situ hybridization signals in mucosal
epithelial cells
19
Liver: No specific pathology. In some cases, necrosis and apoptosis 20
Urogenital tract Kidneys: acute tubular necrosis, in varying degrees and other non-specific features. Positive in situ hybridization signals in the epithelial cells of
the distal tubules
21
Bone marrow In some cases, reactive hemophagocytosis 9
Adrenal gland Necrosis and infiltration of monocytes and lymphocytes 14
Thyroid gland Destruction of follicular epithelial cells, several apoptotic cells 5
Testes Germ cell destruction, apoptotic spermatogenetic cells 7
Modified from The American Journal of Pathology, Vol. 170, No. 4, April 2007
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Table 2
The Neurology of COVID-19 due to SARS-CoV-2.
Neurologic diagnosis Features City/Country Author [Ref]
Central nervous system symptoms







Tian et al. [70]
Chen et al. [71]
Li et al. [62]
Agitation & Delirium 69% agitation (58 ICU patients)
65% delirium (58 ICU patients)
67% pyramidal tract signs
Strasbourg, France Helms et al. [91]
Impaired Consciousness 22% (fatal cases vs. 1% non-fatal cases)
14.8% (severe cases vs. 2.4% non-severe cases)
Wuhan, China
Wuhan, China
Chen et al. [71]
Mao et al. [3]
Anosmia, hyposmia 5.1% (cases from 3 hospitals)
85.6% (cases from 12 hospitals)
Wuhan, China
Europe
Mao et al. [3]
Lechien et al. [4]
Dysgeusia 5.6% (cases from 3 hospitals)
88% (cases from 12 hospitals)
Wuhan, China
Europe
Mao et al. [3]
Lechien et al. [4]
Central nervous system diseases




Large-vessel ischemic stroke 11
Hemorrhagic stroke 1
Cerebral sinus thrombosis 1
1% to 6% (pooled analysis)









Mao et al. [3]
Li et al. [62]
Aggarwal et al. [84]
Helms et al. [91]
Oxley et al. [129]
Frontotemporal hypoperfusion 58 ICU patients with severe COVID-19, 45 survived (33% had frontal lobe
behavioral signs)
11/11 CBF-ASL-MRI frontotemporal hypoperfusion
Strasbourg, France Helms et al. [91]
Arterial & Venous Thromboses 184 patients from 3 hospitals
31% thrombotic complications including pulmonary embolism in 81%
27% venous thromboses
3.7% arterial thromboses
3 patients with multiple arterial thromboses of legs, hands, brain, associated with
anticardiolipin IgA and anti–β2-glycoprotein-I IgA and IgG antibodies
3 patients with multiple arterial thromboses and multi-organ failure due to
coronavirus attachment to ACE2 receptors, viral invasion of endothelial cells,





Klok et al. [92]
Zhang et al. [93]
Varga et al. [36]
Subarachnoid hemorrhage 1 patient with Immune thrombocytopenic purpura France Zulfiqar et al. [94]
Acute Hemorrhagic Necrotizing
Encephalopathy
Brain MRI showed bilateral hemorrhagic rim-enhancing lesions in the thalami,
medial temporal lobes, and subinsular regions, probably associated with cytokine
storm syndrome
Detroit, USA Poyiadji et al. [61]
Meningoencephalitis Seizures, neck rigidity, CSF pleocytosis (12/μ/L). CSF-RT-PCR positive for SARS-
CoV-2.
Japan Moriguchi et al. [102]
Encephalopathy Decreased level of consciousness with COVID-19. Negative CSF & CT brain; EEG:
diffuse encephalopathy




Filatov et al. [103]
Ye et al. [104]
Seizures Recurrent generalized tonic-clonic seizures; normal CT/MRI, CSF-RT-PCR
negative for SARS-CoV-2
Iran Karimi et al. [105]
Myelitis COVID-19 pneumonia, high fever (40 °C), acute flaccid paraplegia Wuhan, China Zhao et al. [113]
Peripheral nervous system & muscle
Neuritic pain 8.9% Wuhan, China Mao et al. [3]
Guillain-Barré syndrome First case in China 61-year-old woman
First case in USA 54-year-old man




Zhao et al. [108]
Virani et al. [109]
Toscano et al. [110]
Miller Fisher Syndrome, Polyneuritis
Cranialis
Neurosensory hearing loss
50-year-old man with diplopia due to external ophthalmoplegia, ataxia and
areflexia
39-year-old man with diplopia from bilateral abducens palsy, global areflexia but
no ataxia
Old woman from Thailand
Madrid, Spain
Bangkok, Thailand
Gutiérrez-Ortiz et al. [112]
Sriwijitalai & Wiwanitkit
[113]






Huang et al. [63]
Myopathies 10.7% (19.3% severe vs. 4.8% non-severe) Wuhan, China Mao et al. [3].
Rhabdomyolysis 33% have increased creatine kinase




Jin & Tong [121]
Suwanwongse et al. [122]
Irreversible respiratory failure
Case-fatality rates (CFR) 81% of 72,314 COVID-19 infections are mild but 20% or 8255 are severe (CFR
8.0% - 14.8%) or critical (CFR 49%)




Wu & McGoogan [124]
Several [67,69,74,80,106]
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conceivably may have been related to viral particles and viral genome
sequences isolated from the cytoplasm of neurons in the hypothalamus
[47,58].
Table 1 summarizes the pathological lesions produced by SARS-
CoV-1 including, in addition to respiratory tract lesions and pneumonia
with severe alveolar damage, viral injury in mucosal cells of the in-
testine, acute tubular necrosis, vasculitis and lymphocyte depletion in
spleen and lymph nodes [46]. According to Guo et al. [54], the pa-
thology of SARS is the result of direct injury caused by the coronavirus
infection of target cells, as well as indirect injury from immune re-
sponses, circulatory dysfunction, and hypoxia. The exact route of SARS-
CoV-1 infection of the human brain is unknown. Infected monocytes/
macrophages migrating across the blood–brain barrier (BBB) might be
involved [54].
In summary, there is solid evidence of involvement of nervous
system and muscle in human infection by SARS-CoV-1 based on neu-
ropathological studies. However, clinical series of SARS patients with
neurological manifestations are unavailable.
4.2. MERS-CoV in Saudi Arabia
According to Senga et al. [59], following the prodromal symptoms
of fever, chills, cough, and dyspnea present in> 70% of patients, ap-
proximately one-third of the cases infected with MERS-CoV had
myalgia, malaise, and gastrointestinal symptoms. Arabi et al. [60]
provided the only report of neurological involvement in 3 fatal cases
observed during the epidemic outbreak of MERS in Saudi Arabia in
June 2012.
The first patient was a 74-year-old man with a 3-day history of
ataxia, vomiting, confusion, fever, and left hemiparesis; he became
comatose and required respiratory support. CSF was normal and ne-
gative for MERS-CoV. MRI showed multiple bilateral non-enhancing
areas of signal hyperintensity on T2/FLAIR in the periventricular, deep
white matter, subcortical area, corpus callosum, bilateral brachium
pontis, midbrain as well as in the left cerebellum and upper cervical
cord. The second patient was a 57-year-old man who presented with
flu-like illness, fever and a gangrenous toe who developed facial pa-
ralysis, respiratory distress, became comatose and required intubation.
MRI showed bilaterally deep watershed lesions, and scattered foci in
the cortical and subcortical regions of the temporal, parietal, and oc-
cipital lobes. The third patient was a 45-year-old man with cough,
dyspnea, rigors, fever, and diarrhea. He was conscious and had no focal
neurological signs. He developed septic shock and respiratory failure.
MRI showed confluent non-enhancing T2WI/FLAIR hyperintensities
within the white matter of both cerebral hemispheres and along the
corticospinal tract. CSF showed white cell count of 2 cells/mm3, protein
0.85 g/L with negative RT-PCR for MERS-CoV.
Although not recognized as such by the authors, the brain MRI
images are highly suggestive of acute hemorrhagic necrotizing en-
cephalopathy (AHNE), a condition recently reported during the COVID-
19 epidemic outbreak in the USA [61]. In summary, there is almost
complete absence of clinical information on the neurology of MERS and
no pathological data are available, except for a single postmortem
needle biopsy of the brain with normal results.
5. Neurological disease in COVID-19: central nervous system
As indicated earlier, a few reports issued from the original epidemic
outbreak in Wuhan, China [1–3], emphasize the occurrence of neuro-
logical involvement in patients with SARS-CoV-2. A systematic review
published in the Journal of the Neurological Sciences [1] found only 6
articles [3,62–66] from December 2019 to March 2020 addressing the
neurology of COVID-19 and concluded that these complications have
not been studied appropriately, particularly because they may remain
unrecognized in patients with severe illness. Also, it is unclear if some
of the conditions listed here are simply concurrent or if they are
induced by the viral infection. However, given the growing reports of
neurological disease of COVID-19, with others [2,67], we consider it
critical to define the direct neurotropic effect as well as the indirect
virus-induced secondary impact of SARS-CoV-2 infection on the ner-
vous system. We updated the review of published reports as of April 30,
2020, including a number of pre-publication articles, and describe
below the available data on the neurology of COVID-19. Table 2 sum-
marizes this information.
5.1. Headache and alterations of consciousness
During the early symptomatic phase of SARS-CoV-2 infection
in> 1200 patients reported from hospitals in Wuhan [62–66,68,69],
fever occurred in 88%–92%; cough in 67%–69%, fatigue in 26%–51%,
and 36% had myalgia. In a cohort of 262 confirmed cases from Beijing
hospitals [70] 6.5% had headache, compared with 6%–8% in Wuhan
and 13% developed cerebrovascular disease (CVD) [62]. Chen et al.
[71] studied the initial symptoms in a cohort of 113 fatalities of COVID-
19 compared with 161 patients who recovered; early alteration of
consciousness occurred significantly more often in fatal cases (22%)
compared with 1% among those who recovered. Mao et al. [3] also
found impaired consciousness in 14.8% of 214 patients hospitalized due
to severe disease compared with 2.4% in non-severe infections.
Therefore, early onset of headache and decreased responsiveness are
indicators of potential neurological involvement in COVID-19 patients.
5.2. Alterations of smell and taste
The absence or diminished ability to smell (anosmia, hyposmia) or
to taste normally (hypogeusia, dysgeusia) is a common symptom among
COVID-19 patients around the world [4,72–74] and it has been sug-
gested that anosmia could indicate the neurotropic potential of the
coronavirus to invade the brain [75]. Among 214 patients with COVID-
19 from 3 hospitals in Wuhan, China [3] hypogeusia was reported in
5.6% and hyposmia in 5.1%. A much higher incidence of these dis-
orders has been described in European patients. A multi-center study
involving 12 European hospitals conducted by the Young-Otolar-
yngologists of the International Federation of Oto-rhino-laryngological
Societies (YO-IFOS) [4] recruited 417 patients with mild-to-moderate
COVID-19 and found olfactory dysfunction in 85.6% and gustatory
dysfunction in 88%; both symptoms were often associated, and early
olfactory recovery occurred in 44% [4]. In severe COVID-19 cases, al-
terations of smell and taste occurred before any other complaints in
11.8% of the cases. According to Xydakis [72], the American Academy
of Otolaryngology—Head and Neck Surgery and the British Association
of Otorhinolaryngology have recommended adding anosmia-dysgeusia
to the list of primary screening symptoms for SARS-CoV-2 infection.
These symptoms often occur in the absence of nasal congestion or
rhinorrhea in patients with mild or no constitutional symptoms [73,74].
Because of the frequent occurrence of anosmia-dysgeusia, Li and
colleagues [75] suggested that viral neurotropism of SARS-CoV-2 could
result in invasion of the olfactory nerve (cranial nerve I) [30,75], the
olfactory brain and then the brain stem causing the irreversible re-
spiratory failure typical of severe COVID-19. The neurotropism of cor-
onaviruses has been demonstrated before. In 2007, Suzuki et al. [76]
were able to identify coronaviruses in the nasal discharge of patients
who failed to recover olfaction after a cold. Animal models have shown
that the nasal route is a well-recognized pathway for neurotropic
viruses to reach the brain [32,33,71,77]. Given the importance of the
ACE2 receptor in the pathogenesis of SARS-CoV-2 neurotropism, Net-
land and colleagues [78] using mice transgenic for human ACE2 de-
monstrated that the virus enters the brain through the olfactory bulb
and uses rapid transneuronal spread to reach olfactory cortex, basal
ganglia and midbrain (dorsal raphe) nuclei, dorsal motor nucleus of the
vagus, nucleus tractus solitarii and area postrema causing neuronal
death in the absence of encephalitis. A similar pattern of brain invasion
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was demonstrated in human brains from patients with SARS-CoV-1
infection [42,79]. It has been proposed that viral neurotropism could
explain the severity of respiratory failure in COVID-19 [75] and the
absence of dyspnea [80]. Mutations of the S protein of the coronavirus
[81] or variations in population genetics for expression of ACE2 [82]
could determine the divergences in the pattern of respiratory problems
in COVID-19.
5.3. Cerebrovascular disease
COVID-19 may increase the risk for venous and arterial throm-
boembolism associated with inflammation, hypoxia, immobilization,
and diffuse intravascular coagulation.
Only three clinical series of stroke in patients with COVID-19 are
currently available [3,62,84].
A report by Mao et al. [3] described 214 patients with acute COVID-
19 in Wuhan included 58.9% (mean age 58.7 years) severe cases and
41.1% (mean age 49.9 years) non-severe patients. In total, 78 patients
(36.4%) had neurological involvement occurring more often in the se-
vere disease group. Six patients (2.4%) had acute cerebrovascular dis-
ease, 5 of them severe cases (5.5%) that occurred 9 days after onset
(range=1–18 days). Computed tomography (CT) of the brain con-
firmed 4 ischemic strokes and 1 cerebral hemorrhage. Stroke patients
with severe infection were older, had more underlying vascular risk
factors, especially hypertension, and showed fewer typical symptoms of
COVID-19, such as fever and cough.
Also in Wuhan, Li and colleagues [62] reported 221 patients and
found 11 (5%) cases with ischemic strokes mainly from large-vessel
occlusion. A 32-year-old man had cerebral sinus thrombosis and an-
other had cerebral hemorrhage (62-year-old man). Stroke affected more
women (6/11) who were significantly older (71.6 ± 15.7 years) vs.
52.1 ± 15.3 years in the group without stroke; more vascular risk
factors were present including history of hypertension, diabetes, and
previous cerebrovascular disease. Stroke patients had leukopenia and
the values of C-reactive protein (CRP) were higher (mean=51.1mg/L,
range= 1.3–127.9mg/L) than in non-stroke cases (12.1 mg/L,
0.1–212.0mg/L); also, a hypercoagulable tendency was reflected in
significant elevation of D-dimer values (mean=6.9mg/L,
range= 0.3–20.0mg/L) vs. 0.5mg/L (range=0.1–20.0mg/L) in non-
stroke cases (p < .001). Therapy included anti-platelet treatment in 6
cases and anticoagulation in 5. A total of 5 patients with stroke died
(38% mortality).
A first report on 393 patients with confirmed COVID-19 from two
hospitals in the disease epicenter of New York City, USA was recently
published [83] but cerebrovascular disease was not mentioned. How-
ever, strokes from large-vessel occlusion in younger subjects with re-
latively mild COVID-19 in New York have been reported [129].
Aggarwal et al. [84] conducted a pooled analysis of the literature on
the effect on COVID-19 prognosis of either new acute stroke or previous
history of stroke. The analysis included 6 studies from China ranging in
size from 52 to 1099 patients. Cerebrovascular disease occurred in 1%
to 6% of the cohorts corresponding to a non-statistically significant
increase of about 2.5-fold in odds of developing severe COVID-19
among patients with stroke compared with those without.
A number of countries have issued stroke guidelines during the
COVID-19 pandemia. After the first patients with COVID-19 were
hospitalized in Singapore [85], Christopher et al. [86] provided re-
commendations for the early recognition and treatment of stroke in
patients infected with SARS-CoV-2, including the potential use of in-
travenous thrombolysis (TPA) or Endovascular Therapy (EVT) with
mechanical thrombectomy in COVID-19 patients. A similar consensus
was published in India [87].
In China, Jin et al. [88] encouraged neurologists to consider both
ischemic and hemorrhagic strokes as potential complications of COVID-
19. Intracerebral bleed and subarachnoid hemorrhage may be linked to
arterial hypertension induced by binding of SARS-CoV-2 to ACE2
receptors and thrombocytopenia [89,90]. The risk of ischemic stroke is
linked to SARS-CoV-2 infection among critically ill elderly patients with
vascular risk factors, such as hypertension, diabetes mellitus, hyperli-
pidemia, smoking and history of previous stroke or transient ischemic
attacks (TIA). Increased serum levels of D-dimer could enhance the risk
of thrombosis and embolism [89,90].
5.4. Frontotemporal hypoperfusion
Helms and her colleagues [91] from Strasbourg, France, reported 58
patients with severe COVID-19 treated in two Intensive Care Units
(ICUs). Neurologic findings were encountered in 84% at the time of ICU
admission including agitation (69%); corticospinal tract signs (67%),
such as brisk tendon reflexes, ankle clonus, and bilateral extensor
plantar responses; delirium in 65% (based on the Confusion Assessment
Method for the ICU, CAM-ICU); and, hyperthermia with a fever>
38.5 °C. About 12% had past neurological history of TIA, epilepsy, and
mild cognitive impairment (MCI). Lumbar punctures were performed
on 7 patients; in all CSF showed no cells and CSF RT-PCR was negative
for SARS-CoV-2; a single case had elevated CSF protein and IgG levels.
MRI showed cerebral ischemic strokes in 3/13 (23%) cases, two
asymptomatic patients each had small acute ischemic strokes and 1 had
a subacute stroke, probably preexisting. Linear and nodular enhance-
ment of leptomeningeal spaces on FLAIR and T1 was noted post-con-
trast in 8/13 (62%) patients. Notably, arterial spin labeling (ASL)-per-
fusion MRI demonstrated bilateral frontotemporal hypoperfusion in 11/
11 patients. Electroencephalography showed diffuse bifrontal slowing
consistent with encephalopathy in 1 out of 8 cases. Of interest, 33% of
the 45 survivors presented a dysexecutive syndrome suggestive of
frontal lobe involvement, with alterations of attention, orientation and
poorly organized movements on command.
5.5. Arterial and venous thromboses, subarachnoid hemorrhage, and
coagulopathies
Evaluation of 184 patients with COVID-19 at three Dutch hospitals
[92] found a high incidence (31%) of thrombotic complications, in-
cluding 3 patients with stroke. Venous thrombosis occurred in 27%
(95%CI 17–37%) and arterial thromboses in 3.7% (95%CI 0–8.2%).
Pulmonary embolism was the most frequent thrombotic complication
(n=25, 81%). Advanced age and coagulopathy, defined as sponta-
neous prolongation of PT/PTT (prothrombin time > 3 s or activated
partial thromboplastin time > 5 s), were independent predictors of
thrombotic complications. The authors recommended applying strict
pharmacological thrombosis prophylaxis in all COVID-19 patients ad-
mitted to ICU.
Zhang and colleagues [93] reported 3 patients from China (ages
65–70 years) with severe COVID-19 infection who developed multiple
arterial thromboses associated with anticardiolipin IgA antibodies as
well as anti–β2-glycoprotein-I IgA and IgG antibodies with negative
lupus anticoagulant. Patient 1 had ischemia in the lower limbs bilat-
erally as well as in two fingers of the left hand; CT of the brain showed
bilateral cerebral infarcts in multiple vascular territories, involving
frontal, parietal, occipital lobe and bilateral basal ganglia, brain stem,
and bilateral cerebellar hemispheres. Patient 2 had multiple cerebral
infarctions in the right frontal lobe and bilateral parietal lobe. Patient 3
had multiple cerebral infarctions in bilateral frontal lobes, right frontal,
parietal, temporal and occipital lobes, and bilateral cerebellar hemi-
spheres.
Zulfiqar and associates [94] from France, reported a 65-year-old
woman with SARS-CoV-2 infection with viral pneumonia confirmed by
chest CT. She developed lower-extremity purpura, epistaxis, and pro-
gressive thrombocytopenia with normal PT/PTT. One week later, she
complained of right frontal headache without fever, vomiting, or focal
neurologic deficits. CT of the brain showed a small subarachnoid he-
morrhage in the right frontal lobe. The platelet count had decreased to
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2000 per cubic millimeter and she was treated with platelet transfusion,
prednisolone and eltrombopag with good results. A meta-analysis by
Lippi et al. [95] confirmed the association of thrombocytopenia with
severe COVID-19.
In Zurich, Switzerland, Varga and her colleagues [36] reported
endothelial viral infection by SARS-CoV-2 and endotheliitis in post-
mortem examinations of three patients (71-year-old man, renal trans-
plant recipient, with history of coronary artery disease and arterial
hypertension; 58-year-old woman, obese with history of hypertension;
69-year-old hypertensive man). In addition to the severe respiratory
failure typical of COVID-19, they all developed multisystem organ
failure and vascular complications including myocardial infarction and
mesenteric ischemia requiring small intestine resection. Pathology ex-
amination demonstrated lymphocytic endotheliitis in lung, heart,
kidney, small intestine and liver. Viral inclusions were revealed by
electron microscopy indicating direct viral infection of endothelial cells
accompanied by accumulation of mononuclear inflammatory cells. The
authors [36] postulate that this mechanism could explain the wide-
spread endothelial dysfunction associated with apoptosis and multi-
organ vascular involvement observed in severe COVID-19 infections.
Treatments targeted to halt viral replication or to modify ACE2 re-
ceptors [96–98] could have beneficial effects in COVID-19.
As mentioned earlier [20,84], SARS-CoV-2 infects the host by using
the ACE2 receptors present in the upper airway passages and the
pneumocytes in the alveolar epithelial lining, but also expressed in
endothelial cells in lung, heart, kidney, intestines, and in brain, where it
may protect neurons against ischemic injury [97,98]. ACE2 is the en-
zyme that physiologically counters the activation of the renin-angio-
tensin-aldosterone system (RAAS) degrading angiotensin II to angio-
tensin- (1–7), attenuating vasoconstriction and sodium retention [97].
The use of ACE inhibitors (ACEI) and angiotensin-receptor blockers
(ARBs) during the COVID-19 pandemic was the topic of an extensive
review by Vaduganathan and colleagues [97] who concluded that ACE2
may be beneficial and that the withdrawal of RAAS inhibitors in high-
risk cardiovascular patients may be harmful. This is in agreement with
the results of a retrospective, multi-center study in Hubei province,
China [99], which included 1128 hypertensive patients with COVID-19
demonstrating that the use of ACEI/ARB was associated with lower risk
of all-cause mortality.
5.6. Acute hemorrhagic necrotizing encephalopathy
Poyiadji et al. [61] from Detroit, Michigan, USA, described brain-
imaging findings in a woman in her late fifties who presented with
COVID-19 infection, demonstrated by a positive nasopharyngeal RT-
PCR test for the SARS-CoV-2 virus. CSF showed no bacterial growth and
was negative for Herpes simplex 1–2 virus (HSV), varicella-zoster virus
(VZV), and West Nile virus. Coronavirus could not be tested in the CSF.
CT brain demonstrated bilateral and symmetric hypoattenuation within
the medial thalami with normal CT angiogram and CT venogram. Brain
MRI showed bilateral hemorrhagic rim-enhancing lesions in the tha-
lami, medial temporal lobes, and subinsular regions. The authors con-
cluded that the patient presented acute hemorrhagic necrotizing en-
cephalopathy (AHNE). This rare condition is usually considered a
parainfectious disease [99]; it has been associated with influenza A
(H1N1) and influenza B, parainfluenza, VZV, human herpes viruses
HHV-6 and HHV-7, enteroviruses, the novel reovirus strain serotype 2
(MRV2Tou05), rotaviruses, HSV, rubella, coxsackie A9, and measles
viruses, among which H1N1 and HHV-6 are the most common [99].
AHNE is not an encephalitis and the CSF usually shows no pleocytosis.
It is generally accepted that AHNE may be caused by a “cytokine storm”
[100] resulting in elevation of proinflammatory cytokines including
interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), IL-10, IL-15,
IL-1β, soluble TNF receptor, and interferon-gamma (IFN-γ), plus lym-
phocytes, in particular CD56+ natural killer (NK) cells leading to brain
injury through alterations of the BBB by trypsin and matrix
metalloprotease-9 without vessel wall disruption. AHNE may also occur
following vaccination, in particular with the DPTw (diphtheria-tetanus-
pertussis whole cell) vaccine [99]. COVID-19 fatalities have been as-
sociated with a hyperinflammatory syndrome manifested by a growing
HScore [101] decreasing platelet counts, cytopenias, hyperferritinemia,
and increased levels of IL-2, IL-7, granulocyte-colony stimulating factor,
interferon-γ-inducible protein 10, monocyte chemo-attractant protein
1, TNF-α and macrophage inflammatory protein 1-α [100]. Proposed
treatments include steroids, IVIg, and selective cytokine blockade with
anakinra, tocilizumab, or Janus kinase (JAK) inhibition [99,100].
5.7. Encephalopathy, meningitis, encephalitis, and seizures
As reviewed earlier [3,65], decreased level of consciousness is a
neurological manifestation indicative of a severe COVID-19 prognosis.
The causes may range from metabolic encephalopathy associated with
severe hypoxia, post-ictal state following seizures, to acute cere-
brovascular disease caused by endotheliitis and subsequent hematolo-
gical changes or a cytokine storm resulting in AHNE.
There are few reports of meningitis or encephalitis with demon-
stration of SARS-CoV-2 in CSF or brain. In Japan, Moriguchi et al. [102]
reported the case of a 24-year-old man admitted with headache, fever,
fatigue and seizures. On examination, he was in a post-ictal state and
had neck rigidity. CT brain showed no brain edema or lesions. CSF
showed 10 mononuclear and 2 polymorphonuclear cells per μ/L. CSF-
RT-PCR was positive for SARS-CoV-2 but the nasal swab test was ne-
gative. Brain MRI showed hyperintense DWI/FLAIR images on the right
mesial temporal lobe and the inferior horn of the right ventricle con-
sistent with encephalitis and ventriculitis.
Filatov et al. [103] reported a second case of encephalopathy from
Florida, USA, affecting a 74-year-old man with a previous stroke who
became poorly responsive with COVID-19. CSF was normal and CSF-
RT-PCR was negative. Brain imaging showed no new lesions and EEG
was consistent with diffuse encephalopathy. He developed respiratory
failure and required intubation and respiratory support.
In Wuhan, China, Ye et al. [104] reported a male COVID-19 patient
with fever, shortness of breath and myalgias who became confused.
Meningeal signs were positive and extensor plantar responses were
elicited. Lumbar puncture showed an opening pressure of 220mmHg
and normal cells, protein and glucose. CSF was negative for SARS-CoV-
2 and the brain CT was normal. The patient recovered and was dis-
charged from the hospital. Two consecutive SARS-CoV-2 swab tests
were negative.
In Iran, Karimi et al. [105] reported a previously healthy 30-year-
old woman with COVID-19 who was admitted to hospital with re-
current generalized tonic-clonic seizures. CSF and brain MRI were
normal. CSF-RT-PCR for SARS-CoV-2 was negative. Seizures were
treated and the patient was discharged.
In summary, the paucity of reports of encephalitis or meningitis in
COVID-19 is unexpected given the high neurotropic potential of SARS-
CoV-2 [106]. The few cases of meningoencephalitis conceivable may be
the consequence of the extremely high fatality rate of respirator-de-
pendent COVID-19 patients, perhaps caused by direct injury of the re-
spiratory centers in the brainstem. Detailed post-mortem neuropatho-
logical studies [107] should answer this dilemma.
6. Neurological disease in COVID-19: peripheral nervous system &
muscle
Compared with the reports of CNS involvement in COVID-19 the
bibliography describing PNS and muscle pathology is more limited.
6.1. Guillain-Barré syndrome
Zhao et al. [108] from Shanghai, China, reported the first case of
Guillain-Barré syndrome (GBS) associated with COVID-19 in a 61-year-
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old woman who had returned from Wuhan; she did not report fever or
respiratory symptoms but complained of weakness of both legs and
severe fatigue. On examination she had symmetric weakness and are-
flexia of both legs and feet (Medical Research Council, MRC 4/5) that
progressed over the next 3 days (MRC 3/5). Lymphocytopenia and
thrombocytopenia were noted. CSF cell counts were normal with ele-
vated protein (124mg/dL). Nerve conduction studies showed delayed
distal latencies and absent F waves consistent with demyelinating
neuropathy. With a diagnosis of GBS she was treated with IVIg. On day
8, oropharyngeal swabs were positive for SARS-CoV-2, suggesting a
parainfectious profile for GBS, instead of the classic postinfectious one.
In the U.S., a 54-year-old male with confirmed COVID-19 and a
history of fever, cough and Clostridium difficile colitis of recent onset
developed difficulty breathing and weakness and diminished reflexes of
arms and legs eventually diagnosed as GBS [109].
Toscano and colleagues [110] reported 5 patients with GBS from
three hospitals in northern Italy during the COVID-19 outbreak. Patient
1: A 77-year-old woman with abrupt onset of paresthesias in legs and
hands that progressed in 36 h to areflexic tetraplegia without bulbar
signs. Seven days earlier she had fever, cough, and had developed
pneumonia positive for SARS-CoV-2. NCV/EMG confirmed an axonal
variant of GBS. The first CSF was normal but the second one showed
high protein (101mg/dL); CSF-RT-PCR was negative twice. During IVIg
treatment, she developed bulbar symptoms with dysphagia and tongue
weakness, which required assisted ventilation. Patient 2: A 23-year-old
man with a 2-day history of mastoid pain, complete facial weakness,
ageusia and leg paresthesias. Ten days earlier, the patient had fever and
sore throat. On exam he had complete bilateral facial palsy, areflexia
and sensory ataxia. EMG confirmed lower-extremity axonal sensory-
motor neuropathy with sural nerve sparing and decreased facial nerve
cMAP. CSF protein was high (1123mg/dL) with negative virus test and
anti-ganglioside antibodies. He was treated with IVIg with some im-
provement. Patient 3: A 55-year-old man with 10 days of fever, cough
and COVID-19 pneumonia; he developed neck pain, paresthesias in the
4 limbs and lower leg weakness. On day 12, he developed areflexic
tetraparesis with severe axonal neuropathy. CSF showed elevated pro-
tein (123mg/dL) and a negative coronavirus test. He developed facial
diplegia and respiratory failure with IVIg and required assisted venti-
lation due to neuromuscular impairment. Patient 4: A 76-year-old man
with a 5-day history of cough and anosmia evolving into COVID-19
pneumonia. He was admitted with low-back pain and leg weakness that
progressed rapidly to areflexic tetraparesis. CSF was normal with a
negative virus test. IVIg treatment produced motor improvement more
evident in the arms but he was still unable to walk. Patient 5: A 61-year-
old man with a one-week history of asthenia, anosmia and ageusia.
Noticed problem climbing stairs and leg paresthesias and was unable to
stand up on awakening. He had generalized areflexia and paraparesis.
COVID-19 oropharyngeal test was negative and CSF was normal with
negative coronavirus CSF-RT-PCR. Anti-ganglioside antibodies were
negative. On the second day of IVIg therapy, he developed flaccid tet-
raplegia with facial weakness and dysphagia; he eventually required
tracheostomy and assisted ventilation. Serum SARS-CoV-2 antibodies
were positive on admission. In sum, GBS occurred 5 to 10 days after
onset of COVID-19 symptoms, a typical interval. Clinical neurophy-
siology was consistent with axonal-type GBS in 3 cases and demyeli-
nating-type in 2 patients. Post-Gadolinium MRI showed enhancement
of caudal nerve roots in 2 patients and the facial nerve in one. All pa-
tients were treated with IVIg and Patients 1 and 3 received two cycles.
A similar treatment was used in GBS patients during the MERS outbreak
[111].
6.2. C. Miller Fisher syndrome, polyneuritis cranialis
Gutiérrez-Ortiz and her colleagues [112] from Madrid, Spain, re-
ported two patients with clinical manifestations of PNS involvement in
COVID-19. Patient 1 was a 50-year-old man with a 2-day history of
fever, vertical diplopia, perioral paresthesias, anosmia, ageusia, and
unsteadiness. He had a broad ataxic gait and global areflexia. On
neuroophthalmologic examination he showed right hypertropia in all
fields of gaze, severe limitation of adduction and down-gaze move-
ments of right eye, plus left eye nystagmus on left gaze consistent with
right internuclear ophthalmoparesis and right fascicular oculomotor
palsy. Anti-ganglioside antibody GD1b-IgG was positive as well as the
SARS-CoV-2 test. CSF showed no cells and a protein of 80mg/dL. CSF-
RT-PCR was negative for COVID-19. He was diagnosed with Miller
Fisher syndrome (external ophthalmoplegia, ataxia and areflexia) with
good response to IVIg.
Patient 2 was a 39-year-old man with acute onset of diplopia. He
had history of diarrhea and fever, ageusia, and overall fatigue; he tested
positive for COVID-19. Neuroophthalmologic exam was consistent with
bilateral abducens palsy. He had global areflexia but no motor weak-
ness. All CSF tests were negative including SARS-CoV-2; CT brain was
normal. Two weeks later he had made spontaneous recovery of the
diplopia, the ageusia and the areflexia. He was diagnosed with poly-
neuritis cranialis or with incomplete Miller Fisher syndrome sine ataxia.
As with the GBS patient reported above, the cranial nerve involvement
appears to be parainfectious (not due to direct viral neurotropism) but
immune-mediated with presence of GD1b antibodies and positive re-
sponse to IVIg.
A single case of de novo neurosensory hearing loss was reported in a
woman with COVID-19 from Thailand [113].
6.3. Myelitis
Zhao et al. [114] from Wuhan, China, reported a case of a 66-year-
old man with fever and fatigue for two days from COVID-19 pneu-
monia. After high fever at night (40 °C), he developed acute flaccid
paralysis of the legs along with urinary and bowel incontinence. He had
decreased strength in the arms (MRC 3/5) with normal bilateral re-
flexes in upper extremities and flaccid paralysis in the legs (MRC 0/5)
with bilateral hyporeflexia but without pathologic reflexes. Sensation
was intact in the arms but was globally impaired in both legs with a T10
sensory level. CT brain revealed basal ganglia and paraventricular la-
cunar infarctions. CSF and MRI were not done due to pandemic pre-
ventive measures. A possible cytokine storm in response to SARS-CoV-2
infection was diagnosed based on the high fever, leukocytosis, low
serum iron (1.80 μmol/L, normal= 10.6–36.7 μmol/L), elevated serum
ferritin (> 2000 ng/mL, normal= 21.81–274.6 ng/mL) and high levels
of CRP, serum amyloid protein, procalcitonin, and interleukin-6. Fol-
lowing treatment, muscle strength in both upper limbs recovered (MRC
4/5) with minimal improvement in the legs (MRC 1/5). Possible in-
fectious causes of myelitis were ruled out [115], including Mycoplasma
pneumoniae [116], Chlamydia pneumoniae, Epstein–Barr virus (EBV),
influenza A-B virus, parainfluenza virus, adenovirus, coxsackieviruses,
cytomegalovirus (CMV), and respiratory syncytial virus. Tuberculosis
infection was negative. The authors postulated that myelitis was the
result of direct SARS-CoV-2 given that ACE2 receptors are expressed on
the surface membranes of spinal cord neurons [117] combined with a
cytokine storm syndrome [99,100].
6.4. Myasthenia Gravis (MG)
The International MG/COVID-19 Working Group [118] published
the guidance for the management of myasthenia gravis (MG) and
Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19
pandemic.
6.5. Myopathies
As mentioned earlier, fatigue occurred in 26%–51% of patients with
COVID-19 in China [63], 36% had myalgia and increased creatine ki-
nase (CK) was present in 33% of patients [64–66]. There are no reports
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of electromyography or muscle histopathology. Viral myositis occurred
with MERS [119] and SARS [42,47–49]. Rhabodomyolysis was re-
ported in patients with acute renal failure during SARS [120] and there
are two reports [121,122] during COVID-19. Guidon and Amato [123]
published a guide for the management of immune therapies and sup-
port groups for patients with neuromuscular disorders during the
COVID-19 emergency.
7. Conclusions
We conclude from this comprehensive review of current literature
that patients with COVID-19 frequently suffer substantial neurological
involvement. According to the analysis of 72,314 cases from China
[124], the large majority of SARS-CoV-2 infections (81%) are mild and
subjects recover entirely, while about 20% (8255 cases) develop re-
spiratory symptoms ranging from severe (case-fatality rate, CFR
8.0%–14.8%) to critical (CFR 49%) particularly among elderly subjects
with multiple risk factors. However, many severe cases occur in young
people after trivial symptoms of the infection [125].
Although the a priori impression is that CNS injury occurs pre-
dominantly as a result of metabolic and inflammatory responses oc-
curring in elderly patients admitted to intensive care units (ICU), a
direct viral attack might be a more likely explanation for the extremely
high mortality. Vincent & Taccone [126] point out that once old age,
frailty, disability, comorbidities, or lack of personnel and equipment are
discounted, most ICU patients can be supported by invasive mechanical
ventilation until the lungs recover [127]. This is not to the case with
COVID-19.
We hypothesize that SARS-CoV-2, like other human coronaviruses,
has neurogenic properties that result in anosmia in 85.6% of the cases
[4] occurring shortly after the virus reaches ACE2 receptors in the nasal
epithelium at the time of contagion. Given the relative absence of nasal
congestion and rhinorrhea [66,67], anosmia likely results from viral
presence in the olfactory bulbs [69]. In about half of the cases (44%),
the defense mechanisms control the infection and early olfactory re-
covery occurs [4]. In some of the remaining patients, the viral neuro-
tropism of SARS-CoV-2 probably invades the brain via axonal transport
and transneuronal spread from the olfactory nerves to the rhinence-
phalon finally reaching the brainstem causing the irreversible re-
spiratory failure of severe COVID-19, typically characterized by lack of
dyspnea [74].
Concurrently, the virus proliferates and attaches to ACE2 receptors
present in the upper airway and in pneumocytes in the alveolar epi-
thelial lining, as well as in endothelial cells of the lungs, heart, kidney,
and intestine [91–93], resulting in generalized endotheliitis [91] that
causes severe pneumonia, multi-organ collapse including heart failure,
hepatorenal syndrome, coagulopathy and thrombotic state. Widespread
viral invasion of the vascular endothelium apparently may increase the
risk of blood clots that leads to concomitant cardiovascular and cere-
brovascular events, perhaps the most serious complications of COVID-
19 infection. The immune response to the viral proliferation has been
poorly studied but includes the effects of the cytokine storm syndrome
[100]. While the acute and residual effects of SARS-CoV-2 infection
have come into focus, as of this writing there are no reports of the long-
latency effects observed in subjects acutely infected with non-cor-
onaviruses.
8. Recommendations
It is clear that information on the neurology of COVID-19 is frag-
mentary at best due to the emergency arising from local outbreaks
worldwide with massive numbers of patients challenging the health
services. The same is true of the pandemic at large, and, as expressed by
Lipsitch and colleagues [128], epidemiological studies are needed to
provide solid information on total numbers of cases, including mild
ones, risk factors and timing of transmission, severity and attack rate; as
well as risk factors for severe outcomes including death, and timing and
intensity of infectiousness determined by viral shedding studies.
There is an urgent need to understand the neurotropic potential of
SARS-CoV-2 and the frequency of these complications; the traditional
methods of neurology including the time-honored clinicopathological
correlation should provide much-needed answers. The Environmental
Neurology Specialty Group of the World Federation of Neurology
(ENSG-WFN) issued an appeal [5] to neurological societies around the
globe to develop national or regional COVID-19 neuroepidemiological
databanks. Neurologists and physicians at the front line of this pan-
demic are asked to report to each society all cases of new-onset, acute,
delayed and long-latency neurological disorders associated with SARS-
CoV-2 infection during the current COVID-19 pandemic. The worldwide
response to this pandemic encourages us to believe that regional neu-
rologists and physicians, government authorities, and scientists with
expertise in Public Health, epidemiology, infectious diseases, virology,
neurosciences and other relevant fields will be willing to advise and
assist neurological societies to achieve the goal of creating national and
regional databases. This will also encourage much needed peer-re-
viewed publications on the neurology of COVID-19. We will work to
assure that the results of the national registries are collected, posted and
become freely available at the WFN website [https://wfneurology.org].
This global effort should help the world understand the neurological
impact of COVID-19.
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